To summarize the evidence on the prevalence and preventability of drug-related hospital readmissions. DESIGN: A systematic review was performed of studies that examined drug-related hospital readmissions. PubMed, EMBASE, and the Cochrane Library were searched from inception through August 2016. Reference lists and a citation analysis on Web of Science and Scopus were also consulted. Two reviewers extracted study data with dual assessment of risk of bias. Prevalence and preventability of readmission due to drugs were calculated. Data were qualitatively summarized according to outcome. RESULTS: Nineteen studies met the eligibility criteria. Nine measured readmissions due to drug-related problems, seven due to adverse drug reactions, two due to adverse drug events, and one due to drug-drug interactions. Rates of readmissions due to drugs varied from 3% to 64% (median 21%, interquartile range (IQR) 14-23%). Readmissions were deemed preventable in 5% to 87% of cases (median 69%, IQR 19-84%). Evidence regarding the risk factors for drug-related readmissions and drugs causing these readmissions was inconsistent. CONCLUSION: Although studies show high variability in prevalence and preventability of drug-related hospital readmissions, readmissions due to drugs seem to occur often, especially in older adults. Further research is needed to specify the causes of preventable readmissions and implement effective interventions to reduce medication-related hospital admissions. J Am Geriatr Soc 0:1-7, 2018.
H ospital readmissions pose a major burden for individuals and healthcare systems. Approximately 20% of Medicare beneficiaries experience a planned or unplanned hospital readmission within 30 days after discharge, and unplanned readmissions have an estimated annual cost of $17 billion in the United States. 1, 2 The fact that hospital readmissions are increasingly used as a measure of healthcare quality emphasizes the effect of readmissions on outcomes and health expenditures. 3, 4 This has led to several initiatives such as the Hospital Readmission Reduction Program, which was implemented in 2012 in the United States. This program includes payment penalties for hospitals with excessive readmissions for specific diagnoses such as heart failure and pneumonia. It is expected that the diagnosis list will continue to expand. 5 Similar developments are seen in European hospitals. 6 There is broad discussion about the preventability of readmissions. [7] [8] [9] A systematic review from 2011 estimated that 5% to 79% of hospital readmissions were preventable (median 27%). 10 Consequently, much research has been performed regarding the characteristics of these preventable readmissions to identify individuals at high risk of readmission and develop preventive measures. Several demographic factors, individual characteristics, comorbidities, and social and medical factors are associated with hospital readmissions, [11] [12] [13] [14] [15] and polypharmacy is a frequently cited risk factor. Polypharmacy heightens the risk of drug-related problems. [16] [17] [18] [19] [20] One review indicates that 18% to 38% of individuals report drug-related problems after hospital discharge, 18 although the overall prevalence and preventability of drug-related readmissions is unclear. Studies reported that 4.5 to 24% of hospital readmissions are drug-related; a limited number of studies have assessed the preventability of these readmissions. [21] [22] [23] [24] Because older age contributes to greater drug usage, it is reasonable to hypothesize that drug-related readmissions will occur especially in older adults, but insight into patterns of drugrelated hospital readmissions and risk factors are needed to implement interventions that address problems in pharmacotherapy. Therefore, the aim of this study was to systematically review the evidence on the prevalence and preventability of drug-related hospital readmissions.
METHODS
This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines. 25 
Data Sources and Searches
In collaboration with a medical librarian, a systematic search was conducted using Medical Subject Headings and relevant keywords in PubMed, EMBASE, and the Cochrane Library from the inception date of each database to August 2016 (Appendix S1). The search included terms for the prevalence and preventability of drug-related readmissions. The search strategy was validated by evaluating the extent to which the search retrieved previously obtained references. Additional literature was obtained by hand-searching the reference lists of included studies and through a cited reference search performed on Web of Science and Scopus.
Definitions
An index admission is defined as a first hospital admission, 26 and readmissions are admissions occurring within a specified period after the index admission. 27 Drug-related hospital readmissions are defined as readmissions potentially due to pharmacotherapy, including readmissions due to a lack of appropriate drugs based on guidelines. Studies focus on different types of drug-related readmissions, including readmissions due to drug-related problems (DRPs), adverse drug events (ADEs), adverse drug reactions (ADRs), and medication errors (MEs). A summary of the definitions is provided in Figure 1 . Figure 1 . Association between drug-related problems, adverse drug events, adverse drug reactions, and medication errors. Adapted from Otero and Schmitt with permission 33 .
Study Selection
Two reviewers (EU, NM) independently reviewed titles and abstracts for eligibility. Studies were included if they were published in English or Dutch and examined drugrelated hospital readmissions in adults (aged ≥18). The authors of studies not published in English were contacted to explore whether an English version was available. Studies were excluded if any of the following criteria applied: the readmission outcome could not be derived from the results after consulting the authors (e.g., reporting total readmission rate and mortality as one outcome), the method for identifying drug-related readmissions was unclear (e.g., drug-related readmissions were mentioned somewhere in the text without any specification of the detection method), the study focused on drug abuse or intentional drug overdose, the study focused on a specific drug group (e.g., readmissions due to statins only), or the study concerned a non-peer-reviewed article (e.g., abstracts, posters, presentations).
Full-text articles were obtained for studies that the two reviewers identified as potentially eligible and independently assessed for inclusion, and disagreements were resolved by consensus or a third reviewer (FK).
Data Extraction and Quality Assessment
A data extraction form was developed, tested, and refined. Two reviewers (NM and EU or MJ) extracted study data. Disagreements were resolved by consensus or a third reviewer (FK). Extracted data included study characteristics (e.g., study design, setting, study period), personal characteristics, definitions for drug-related readmissions, the applied methods to detect the drug related readmissions (e.g. interview with patient, database) and assess causality and preventability (e.g., Naranjo criteria, Schumock and Thornton) and the professionals that conducted the assessment and outcomes (e.g. medical specialist, pharmacist, nurse) Authors were contacted when further information was required or if information in the study was unclear. The Strengthening the Reporting of Observational Studies in Epidemiology statement checklist was used to assess the quality of the studies. 34 The number of reviewers and information sources used for the identification of drug-related readmissions were also assessed. It was expected that having move reviewers and sources would increase the identification of drug-related readmissions. Finally, the data extractors specified whether clear definitions of outcomes were presented in the studies (how the causal association between the drug and the readmission and the preventability of the readmission were assessed).
Data Synthesis and Analysis
Meta-analysis was not conducted because of the substantial heterogeneity among the studies. Data were qualitatively summarized according to outcome. Articles were categorized according to the type of drug-related readmission reported (DRPs, ADEs, ADRs, MEs; Figure 1 ). Drugs associated with hospital readmissions were categorized according to the Anatomical Therapeutic Chemical Classification System of the World Health Organization. 35 The prevalence rates of drug-related hospital readmissions were calculated as the number of individuals with drug-related readmissions relative to the total number of individuals with readmissions. Likewise, preventability rates were calculated as the number of individuals with probable or definite preventable drugrelated readmissions relative to the total number of individuals with drug-related readmissions. Prevalence and preventability rates were summarized using medians and their corresponding interquartile ranges (IQRs). Different median prevalence rates were compared according to type of drug-related readmission (DRP, ADE, ADR, ME) and study design (retrospective, prospective). In the case of intervention studies, prevalence and preventability rates were based on the control group. Because studies reported multiple risk factors, the risk factors were included in this review only if at least two studies reported them. Figure 2 , 1743 titles were screened and 1547 records were excluded. Of the 196 full-text articles that were screened, 19 were included. After exclusion of 175 studies, 19 were included. Good similarity was observed between the reviewers for screening (interrater agreement: j = 0.78). Of the 19 studies, 17 (89%) were observational, including 11 retrospective studies, 21, 24, [36] [37] [38] [39] [40] [41] [42] [43] [44] 4 prospective studies, 23,45-47 and 2 case-control studies. 22, 48 The remaining 2 studies were a randomized controlled trial 49 and a before-after study 50 (Appendix S2). Of the 19 studies, 9 measured DRP-related readmissions, 23 39 No study specifically examined readmissions due to MEs. The follow-up time between admission and readmission varied from 28 days to 4.2 years, but measurement of readmissions within 30 days of discharge was most common. Characteristics of the included studies are summarized in Table 1 , with more-detailed descriptions provided in Appendices B and C. The median age of the participant population was 76 (IQR 57-82).
RESULTS

As shown in
The quality of reporting in studies varied; mainly, information on which departments were included and definitions for drug-related readmissions were missing. Forty-two percent of the studies did not define drug-related readmissions (Table 1) . Studies mainly used 2 information sources (47%), with a maximum of 3 (21%), to detect drug-related readmissions. The most common information source was medical chart review (84%). Studies often did not include information regarding laboratory values, participant adherence, and the individual's perspective on whether the readmission was drug-related. The assessment of readmissions mainly included medical specialists (63%) and pharmacists (53%) as reviewers. The inter-reviewer agreement was reported in 11% of the studies, and 1 study 24 described a training session for the reviewers to assess the readmissions.
Prevalence and Preventability
The prevalence of drug-related readmissions could be extracted in 12 of 19 studies that reported readmission rates at the individual level 21, 24, [37] [38] [39] [40] [41] [42] [45] [46] [47] 50 (Appendix S3). Rates of readmission due to drugs varied between studies (range 3-64%, median 21%, IQR 14-23%). Outliers did not significantly change the median and ranges. The highest prevalence rate originated from a study that interviewed patients. The studies mainly used the criteria from Naranjo and colleagues (33%) and author-defined criteria (33%) to assess causality between pharmacotherapy and readmission ( Table 2) . Preventability rates were reported in 8 studies but could be extracted in 4 studies at the individual level 24, 38, 40, 42 (Appendix S3). Readmissions were deemed potentially preventable in 5% to 87% of all drug-related readmissions (median 69%, IQR 19-84%); if the outlier (study with 5%) was excluded, the median increased to 76% (IQR 61-87%). The most often used criteria to assess preventability were the Schumock and Thornton criteria (22%), Howard and colleagues criteria (22%), and author-defined criteria (22%) ( Table 2 ). When stratifying the results according to type of drug-related readmission, a median prevalence rate of 22% (IQR 20-45%) was found for DRP-related readmissions 24, 40, 42, 45, 47, 50 with a median preventability rate of 76% (IQR 61-87%). 24, 40, 42 For ADR-related readmissions, the median prevalence rate was 20% (IQR 7-23%), 21, 38, 41, 46 and one study reported a preventability rate of 5%, 38 although the literature states that ADRs are an inherent risk of drugs and therefore not preventable. An ADR can become preventable and would then be considered an ADE when it occurs for a second time (e.g., a known allergy) or when the individual's characteristics are not adequately evaluated (e.g., no dose adjustment based on poor kidney function).
For ADE-related readmissions, one study reported a prevalence of 13%, without information regarding preventability. 37 One study specifically focused on readmissions due to drug-drug interactions and found a prevalence rate of 16%. 39 No differences were observed for the prevalence of drug-related readmissions for studies that collected data retrospectively or prospectively, probably because of the small sample size. The prevalence did not differ at different readmission time intervals either.
Risk Factors
Nine studies [21] [22] [23] 38, 43, 44, 47, 48, 53 identified risk factors for drug-related readmissions. Cancer and a higher Charlson Comorbidity Index score were identified as risk factors for drug-related readmissions in two studies. 38, 44 Conflicting results were found for age. Three studies found that older age was a risk factor, 21,43,47 whereas a fourth 38 found the opposite, and a fifth 48 found no association. The same was true for sex. Four studies found no association, 21, 38, 43, 48 and one study reported that men were more likely to revisit a hospital for a pharmacotherapy-related problem. 44 
Drug Classes
Ten studies reported on drug groups that caused hospital readmissions. 21 
DISCUSSION
This is the first systematic review to summarize the evidence on the prevalence and preventability of specifically drug-related hospital readmissions. The findings of this review suggest that pharmacotherapy is an important cause of hospital readmissions. Rates of readmission due to drugs varied from 3% to 64% (median 21%, IQR 14-23%). The median proportion of these readmissions that were deemed to be preventable was 69% (IQR 19-84%). The high variability in rates makes it difficult to state how often drugrelated readmissions could be expected to occur. Because only a limited number of studies have focused on preventability, an accurate estimate of the proportion of preventable drug-related readmissions is impossible. Differences in the type of readmissions that were assessed, the population studied, the methods used to assess causality and preventability, and the sources used to assess readmissions can explain the differences in prevalence and preventability rates of readmission between the studies. The studied populations were mainly older adults (median age 76, IQR 57-82). Conflicting results were found for age as a risk factor for drug-related readmissions, but because a higher Charlson Comorbidity Index score was found as a risk factor, and older adults have more comorbidities, it is reasonable to expect that older adults are at higher risk of drug-related readmissions.
A previous systematic review focused on all-cause readmissions and did not further specify the role of drug-related hospital readmissions. It found a median preventability rate of 27% (range 5-79%. 10 Based on the current systematic review, 20% of readmissions are due to drugs, and 69% of these readmissions are regarded as preventable, which is higher than reported in a previous systematic review 10 for all-cause readmissions. However, the studies in the current review, even the one focusing on the preventability of readmissions, do not provide insight into how the drug-related readmissions can be prevented (e.g., medication reconciliation, medication review, or focus on adherence).
A better understanding of the causes of readmissions is needed to implement effective interventions. For example, the included studies did not specify whether a drug-related readmission was causally related to the index admission. Therefore, it is possible that these studies included readmissions that were the result of actions in the primary care setting and were beyond the control of the hospital. It is also important to understand how an individual handles medication. The individual's perspective was often lacking in the studies. Individual perspectives do not always align with those of healthcare providers and can provide new information that could influence the assessment of readmissions. [54] [55] [56] Individuals can be a valuable information source because of their particular knowledge of the circumstances around their readmissions regarding recent medication changes, use of over-the-counter drugs, ADRs, and adherence to the therapy. The highest prevalence rate found in this review originated from a study that interviewed patients. Many studies failed to report the symptoms that a drug caused. For example, use of corticosteroids could result in a readmission because of bleeding, a fall (osteoporosis), or hyperglycemia. The intervention to prevent a readmission due to drugs may differ based on the reason for readmission.
The strengths of this review are the originality of its aim and the extensive validated search strategy, but this study also has some limitations that need to be considered when interpreting the findings. First, the interrater agreement (k = 0.78) was slightly below the benchmark of 0.8, although the search strategy was validated and built in collaboration with a medical librarian. We conducted an extensive search in multiple databases with reference list checks and therefore do not expect that we missed relevant articles. Nevertheless, publications could have been missed in the grey literature or due to language barriers. We contacted authors to explore whether an English version was available, but two studies were excluded because of language barriers. Given the number of studies included in our review, it is unlikely that the overall conclusions would change meaningfully if missed studies were included. Furthermore, these studies found drug-related readmission rates of 25% 57 and 36%, 58 which are comparable with the prevalence rates reported in the included studies.
No meta-analysis could be performed because of the considerable heterogeneity among the studies, and therefore the data were analyzed in a qualitative manner using medians and corresponding IQRs to compare prevalence rates. The profound differences between the studies with respect to study characteristics, participant populations, definitions, and methods of identification of drug-related readmissions limit comparability. Most studies were single centered and moderately sized, limiting external generalizability. The prevalence of drug-related readmissions might be underestimated, because moderately sized studies mainly examined readmissions to the same hospital, and information from participants was not included.
Future studies should include larger sample sizes from multiple hospitals and multiple departments, and the process of identifying drug-related readmissions should be standardized. For example, a protocol that includes a preventability assessment and individuals' perspectives could be developed. Studies should also focus on causes of drug-related readmissions and possible interventions. An important knowledge gap remains regarding the risk factors for drug-related readmissions that should be addressed as part of future research.
In conclusion, this review demonstrated that the median prevalence of drug-related admissions was 21% (IQR 14-23%) with a preventability of 69% (IQR 19-84%). Drug-related readmissions seem to occur especially in older adults. It is likely that the wide variation in the prevalence and preventability rates was due to heterogeneity among the studies. Further research on drug-related readmissions is required to understand the causes of these readmissions. Such understanding will aid in the development and implementation of effective interventions.
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